New data on Selvita's SEL24

16 April 2018

Despite announcing that positive trial results had been published on its lead cancer drug candidate, Polish biotech firm Selvita (PL: SLV) saw its share price dip 1.33% to 59.20 zlotys this morning.

The company said that it has published recent results of a research concerning the therapeutic potential of SEL24 in acute myeloid leukemia (AML) online in Oncotarget, on March 30, 2018.

SEL24 is a Selvita-developed first-in-class orally available dual PIM/FLT3 kinase inhibitor with a unique activity profile, currently investigated for the treatment of patients with relapsed/refractory (R/R) AML. The program entered first-in-human study in early 2017. In March 2017, Selvita signed a global license agreement with family-controlled drugmaker Menarini Group for further research, development, manufacture and commercialization of SEL24/MEN1703 worldwide.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK